211 related articles for article (PubMed ID: 28260166)
1. Population PBPK modelling of trastuzumab: a framework for quantifying and predicting inter-individual variability.
Malik PRV; Hamadeh A; Phipps C; Edginton AN
J Pharmacokinet Pharmacodyn; 2017 Jun; 44(3):277-290. PubMed ID: 28260166
[TBL] [Abstract][Full Text] [Related]
2. Physiologically-based pharmacokinetic modeling to predict the clinical pharmacokinetics of monoclonal antibodies.
Glassman PM; Balthasar JP
J Pharmacokinet Pharmacodyn; 2016 Aug; 43(4):427-46. PubMed ID: 27377311
[TBL] [Abstract][Full Text] [Related]
3. Application of population physiologically based pharmacokinetic modelling to optimize target expression and clearance mechanisms of therapeutic monoclonal antibodies.
Reig-Lopez J; Tang W; Fernandez-Teruel C; Merino-Sanjuan M; Mangas-Sanjuan V; Boulton DW; Sharma P
Br J Clin Pharmacol; 2023 Sep; 89(9):2691-2702. PubMed ID: 37055941
[TBL] [Abstract][Full Text] [Related]
4. Scale-up of a physiologically-based pharmacokinetic model to predict the disposition of monoclonal antibodies in monkeys.
Glassman PM; Chen Y; Balthasar JP
J Pharmacokinet Pharmacodyn; 2015 Oct; 42(5):527-40. PubMed ID: 26364301
[TBL] [Abstract][Full Text] [Related]
5. Population pharmacokinetics of trastuzumab in patients with HER2+ metastatic breast cancer.
Bruno R; Washington CB; Lu JF; Lieberman G; Banken L; Klein P
Cancer Chemother Pharmacol; 2005 Oct; 56(4):361-9. PubMed ID: 15868146
[TBL] [Abstract][Full Text] [Related]
6. Bayesian Population Physiologically-Based Pharmacokinetic (PBPK) Approach for a Physiologically Realistic Characterization of Interindividual Variability in Clinically Relevant Populations.
Krauss M; Tappe K; Schuppert A; Kuepfer L; Goerlitz L
PLoS One; 2015; 10(10):e0139423. PubMed ID: 26431198
[TBL] [Abstract][Full Text] [Related]
7. Mechanistic Physiologically Based Pharmacokinetic (PBPK) Model of the Heart Accounting for Inter-Individual Variability: Development and Performance Verification.
Tylutki Z; Mendyk A; Polak S
J Pharm Sci; 2018 Apr; 107(4):1167-1177. PubMed ID: 29175411
[TBL] [Abstract][Full Text] [Related]
8. Using Bayesian-PBPK modeling for assessment of inter-individual variability and subgroup stratification.
Krauss M; Burghaus R; Lippert J; Niemi M; Neuvonen P; Schuppert A; Willmann S; Kuepfer L; Görlitz L
In Silico Pharmacol; 2013; 1():6. PubMed ID: 25505651
[TBL] [Abstract][Full Text] [Related]
9. Can Population Modelling Principles be Used to Identify Key PBPK Parameters for Paediatric Clearance Predictions? An Innovative Application of Optimal Design Theory.
Calvier EAM; Nguyen TT; Johnson TN; Rostami-Hodjegan A; Tibboel D; Krekels EHJ; Knibbe CAJ
Pharm Res; 2018 Sep; 35(11):209. PubMed ID: 30218393
[TBL] [Abstract][Full Text] [Related]
10. Utility of physiologically based pharmacokinetic modeling to predict inter-antibody variability in monoclonal antibody pharmacokinetics in mice.
Liu S; Humphreys SC; Cook KD; Conner KP; Correia AR; Jacobitz AW; Yang M; Primack R; Soto M; Padaki R; Lubomirski M; Smith R; Mock M; Thomas VA
MAbs; 2023; 15(1):2263926. PubMed ID: 37824334
[TBL] [Abstract][Full Text] [Related]
11. Model-based meta-analysis for development of a population-pharmacokinetic (PPK) model for Vitamin D3 and its 25OHD3 metabolite using both individual and arm-level data.
Ocampo-Pelland AS; Gastonguay MR; French JF; Riggs MM
J Pharmacokinet Pharmacodyn; 2016 Apr; 43(2):191-206. PubMed ID: 26872884
[TBL] [Abstract][Full Text] [Related]
12. Development of a PBPK model for monoclonal antibodies and simulation of human and mice PBPK of a radiolabelled monoclonal antibody.
Heiskanen T; Heiskanen T; Kairemo K
Curr Pharm Des; 2009; 15(9):988-1007. PubMed ID: 19275663
[TBL] [Abstract][Full Text] [Related]
13. Whole-Body Physiologically Based Pharmacokinetic Modeling of Trastuzumab and Prediction of Human Pharmacokinetics.
Bae DJ; Kim SY; Bae SM; Hwang AK; Pak KC; Yoon S; Lim HS
J Pharm Sci; 2019 Jun; 108(6):2180-2190. PubMed ID: 30716331
[TBL] [Abstract][Full Text] [Related]
14. Whole-body physiologically based pharmacokinetic population modelling of oral drug administration: inter-individual variability of cimetidine absorption.
Willmann S; Edginton AN; Kleine-Besten M; Jantratid E; Thelen K; Dressman JB
J Pharm Pharmacol; 2009 Jul; 61(7):891-9. PubMed ID: 19589231
[TBL] [Abstract][Full Text] [Related]
15. Optimal Affinity of a Monoclonal Antibody: Guiding Principles Using Mechanistic Modeling.
Tiwari A; Abraham AK; Harrold JM; Zutshi A; Singh P
AAPS J; 2017 Mar; 19(2):510-519. PubMed ID: 28004347
[TBL] [Abstract][Full Text] [Related]
16. Integration of physiological changes during the postpartum period into a PBPK framework and prediction of amoxicillin disposition before and shortly after delivery.
Dallmann A; Himstedt A; Solodenko J; Ince I; Hempel G; Eissing T
J Pharmacokinet Pharmacodyn; 2020 Aug; 47(4):341-359. PubMed ID: 32748112
[TBL] [Abstract][Full Text] [Related]
17. Two-pore physiologically based pharmacokinetic model validation using whole-body biodistribution of trastuzumab and different-size fragments in mice.
Li Z; Li Y; Chang HP; Yu X; Shah DK
J Pharmacokinet Pharmacodyn; 2021 Oct; 48(5):743-762. PubMed ID: 34146191
[TBL] [Abstract][Full Text] [Related]
18. Physiologically based predictions of the impact of inhibition of intestinal and hepatic metabolism on human pharmacokinetics of CYP3A substrates.
Fenneteau F; Poulin P; Nekka F
J Pharm Sci; 2010 Jan; 99(1):486-514. PubMed ID: 19479982
[TBL] [Abstract][Full Text] [Related]
19. Modelling the effect of insulin on the disposal of meal-attributable glucose in type 1 diabetes.
García-García F; Hovorka R; Wilinska ME; Elleri D; Hernando ME
Med Biol Eng Comput; 2017 Feb; 55(2):271-282. PubMed ID: 27155940
[TBL] [Abstract][Full Text] [Related]
20. Physiologically-based pharmacokinetic (PBPK) model to predict IgG tissue kinetics in wild-type and FcRn-knockout mice.
Garg A; Balthasar JP
J Pharmacokinet Pharmacodyn; 2007 Oct; 34(5):687-709. PubMed ID: 17636457
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
